Sun Pharma introduces an innovative chemotherapy product in the U.S
Category: #health  By Pankaj Singh  Date: 2019-04-08
  • share
  • Twitter
  • Facebook
  • LinkedIn

Sun Pharma introduces an innovative chemotherapy product in the U.S
  • The chemotherapy product, INFUGEM™, would be the nation’s first & only cancer drug that comes pre-mixed in a formulation that is ready to infuse.
     
  • The incorporation of ready-to-use bags reduces the time taken by complex preparation processes of chemotherapy.

Sun Pharmaceutical Industries Ltd. (Sun Pharma), a renowned Mumbai-based multinational pharmaceutical firm, has reportedly announced the launch of INFUGEM™, an injection of gemcitabine in sodium chloride, in the U.S.

Reports cite, the drug would be the first & only chemotherapy product that comes pre-mixed in a formulation that is ready-to-infuse. The incorporation of ready-to-use bags reduces the time taken by complex preparation processes of chemotherapy, thus lessening exposure and also mitigating inherent patient & provider safety risks.

According to a report by Business Standard, the Indian pharmaceutical firm had already received all the regulatory approvals required for the distribution of the INFUGEM™ injection from the United States Food & Drug Administration back in July, 2018.

Moreover, the company also received approvals for other drugs that were designed for the treatment of ovarian, breast as well as non-small-cell lung cancers and also as a single-agent that helps treat pancreatic cancer.

The CEO-North America at Sun Pharma, Abhay Gandhi stated that the injection is a prominent example of the company’s focus, which is to enhance patient & provider experiences by utilizing high-tech delivery systems as well as new formulations for gold-standard drugs. Gandhi further added that with a rising number of organizations strongly recommending premixed parenteral products’ use due to concerns pertaining to manual compounding & with wide use of gemcitabine for the treatment of various cancers, the time is ideal for the launch of INFUGEM across the U.S.

The injection is the first product that utilizes Sun Pharma’s proprietary technology, which enables premixing of cytotoxic oncology products in a sterile environment & supplied to prescribers through ready-to-infuse final-dosage bags.

According to reports, the product can stay stable at room temperature for over two years, even without preservatives, as compared to other gemcitabine products that remain stable for just 24-hours.



About Author

Pankaj Singh

Email: [email protected]   

Pankaj Singh

Pankaj Singh Develops content for Market Size Forecasters, Algosonline, and a couple of other platforms. A Post Graduate in Management by qualification, he worked as an underwriter in the UK insurance domain before deciding to switch his field of profession. With exp...

Read More

More News By Pankaj Singh

Epizyme gets FDA approval for TAZVERIK™ to treat epithelioid sarcoma
Epizyme gets FDA approval for TAZVERIK™ to treat epithelioid sarcoma
By Pankaj Singh

Epizyme, Inc., a renowned biopharmaceutical company developing new epigenetic therapies, has reportedly announced that the United States Food and Drug Administration has granted the accelerated approval of the company&...

PayPal and UnionPay partner to expand their global consumer base
PayPal and UnionPay partner to expand their global consumer base
By Pankaj Singh

Digital payment applications have simplified cashless transactions by offering payment options in both offline and online mode. Within a short span of time, the digital payment industry has seen significant growth, wit...

Eli Lilly and Company to build a manufacturing unit in North Carolina
Eli Lilly and Company to build a manufacturing unit in North Carolina
By Pankaj Singh

Global pharmaceutical firm, Eli Lilly and Company has recently revealed plans to create over 460 new jobs by investing nearly $470 million in Durham, North Carolina. Reportedly, the project would introduce a brand new ...